N/A
Completed N=6
Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence
Cannabis Use Disorder · Adolescent Behavior
Source: ClinicalTrials.gov NCT03786224 ↗
Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: Continuous Abstinence Via Progressive Declines in Urine THCCOOH — NA ng/mL
Summary
This study is a critically important first-of-its-kind investigation of the potential research utility of using contingency management to examine long-term changes in cannabis use with six months of abstinence. These pilot data will inform a later trial which will focus on testing the longitudinal relationships between adolescent cognition and cannabis use, questions of high and growing public health significance given adolescents' increased access to cannabis with legalization.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Continuous Abstinence Via Progressive Declines in Urine THCCOOH |
NA | — |
Eligibility Criteria
Inclusion Criteria
- Male and female adolescents actively enrolled in a middle or high school in the Boston area who are between the ages of 13 and 19 (inclusive);
- Average use of cannabis at least 3 times per week during the 3 months prior to study enrollment;
- Cannabis use reported within 7 days of study enrollment;
- No immediate plan to discontinue cannabis use;
- Have a parent or legal guardian who is competent and willing to provide written informed consent for the active study phase (if under the age of 18);
- Competent and willing to provide written informed assent for the active study phase (if under the age of 18);
- Competent and willing to provide written informed consent (if age 18 or older);
- Able to communicate in English language;
- Have a parent/guardian who can communicate in English language;
- Able to commit to 27 study visits in approximately 6 months;
- Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the investigator.
Exclusion Criteria
- Any severe developmental delays (including, but not limited to, Autism Spectrum Disorder, Intellectual Disability, and Down Syndrome).
Data sourced from ClinicalTrials.gov (NCT03786224). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.